Drug Profile

Trabectedin - Johnson & Johnson/University of Illinois

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 03 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Illinois
Developer Bristol-Myers Squibb; European Organisation for Research and Treatment of Cancer; Johnson & Johnson; Mario Negri Institute for Pharmacological Research; National Cancer Institute (USA); PharmaMar; Taiho Pharmaceutical
Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer; Soft tissue sarcoma
New Molecular Entity Yes

Marketed Ovarian cancer; Soft tissue sarcoma
Phase III Fallopian tube cancer; Peritoneal cancer
Phase II Leiomyosarcoma; Liposarcoma; Malignant-mesothelioma; Meningioma; Non-small cell lung cancer; Solid tumours
No development reported Breast cancer; Prostate cancer

13 Sep 2024 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
23 Aug 2024 Phase-I clinical trials in Ovarian cancer in Japan (IV) before August 2024 (Otsuka pharmaceutical pipeline, August 2024)
07 Apr 2024 Pharmacodynamics data from a preclinical study in bone cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com